Saturday 17 October 2026
Export KTTA’s income statement to Excel — free account
Pasithea Therapeutics Corp.
KTTA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 75.8% and free cash flow fell 21.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.42
0.01
+2.44%
Follow KTTA
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 27.80 | 10.80 | 5.26 | 2.37 | 0.28 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 170.00 | 36.60 | 17.40 | 9.25 | 3.85 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 3 | 5 | 15 | 8 | 4 | 5 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | (14.57) | 76.74 | — | — | — | |||||
| EBT | — | — | — | — | 0 | (2) | (12) | (16) | (14) | (20) | |||||
| EBT margin, % | — | — | — | — | 0.00 | (14,394.04) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | — | 0 | (2) | (12) | (16) | (14) | (20) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | (0.11) | (4.18) | (10.91) | (13.01) | (12.69) | (2.91) | |||||
| Cash flow | — | — | — | — | (0.11) | (6.10) | (9.43) | (10.44) | (12.70) | (2.16) | |||||
| Capex | — | — | — | — | 0.00 | (0.04) | (0.08) | 0.06 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | (0.11) | (6.14) | (9.51) | (10.38) | (12.70) | (2.16) | |||||
| Book value | — | — | — | — | 0.66 | 98.83 | 33.68 | 19.07 | 13.49 | 7.85 | |||||
| Shares, m | — | — | — | — | 0 | 1 | 1 | 1 | 1 | 7 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | — | — | — | ||||
| P/S | — | — | — | — | — | 0.00 | 33.35 | — | — | — | |||||
| P/B | — | — | — | — | — | 0.36 | 0.38 | — | — | — | |||||
| EV/Sales | — | — | — | — | — | 0.00 | (34.65) | — | — | — | |||||
| EV/FCF | — | — | — | — | — | 10.81 | 1.40 | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (3) | (12) | (13) | (14) | (15) | ||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | — | 0 | |||||
| Free cash flow | — | — | — | — | 0 | (3) | (12) | (13) | (14) | (15) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | 53 | 32 | 14 | 6 | 51 | ||||
| Total debt | — | — | — | — | — | — | 1 | — | — | — | |||||
| Net debt | — | — | — | — | 0 | (53) | (33) | (16) | (7) | (55) | |||||
| Shareholders’ equity | — | — | — | — | 0 | 51 | 42 | 23 | 15 | 55 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (33.06) | (8.11) | (28.30) | (44.78) | (65.93) | (53.54) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (83.61) | (141.31) | (113.31) | 0.00 | |||||
| ROE | — | — | — | — | (0.16) | (8.41) | (29.68) | (48.44) | (72.83) | (58.36) | |||||
Negative figures in brackets.
Fiscal years to Dec 2021 · latest quarter Jan 0001
Charts ten years each
Pasithea Therapeutics Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CNSY Cerenome, Inc. | $14.3M | — (loss-making) | — (loss-making) | −70.43% (below 0%: shrinking) | n/m | −31.46% (below 0%: shrinking) | 100.00% | (2,203.65%) | Compare |
| CLVSQ Clovis Oncology, Inc. | $14.2M | — (loss-making) | — (loss-making) | −19.13% (below 0%: shrinking) | n/m | +11.83% (above 0%: growing) | 71.93% | (144.26%) | Compare |
| BCDA BioCardia, Inc. | $14.2M | — (loss-making) | — (loss-making) | −93.02% (below 0%: shrinking) | n/m | −5.15% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| RVLP RVL Pharmaceuticals PLC | $14.1M | — (loss-making) | — (loss-making) | −2.25% (below 0%: shrinking) | n/m | −734.24% (below 0%: shrinking) | 76.43% | (266.66%) | Compare |
| LPCN Lipocine Inc. | $13.9M | — (loss-making) | — (loss-making) | −69.48% (below 0%: shrinking) | n/m | −60.56% (below 0%: shrinking) | 100.00% | (1,495.11%) | Compare |
| KTTA Pasithea Therapeutics Corp. | $13.7M | — (loss-making) | — (loss-making) | +1,494.04% (above 0%: growing) | n/m | −21.68% (below 0%: shrinking) | 0.00% | 0.00% | |
| ICU SeaStar Medical Holding Corporation | $13.5M | — (loss-making) | — (loss-making) | +81.95% (above 0%: growing) | n/m | +0.43% (above 0%: growing) | 91.22% | (616.42%) | Compare |
| HIND Vyome Holdings, Inc. | $13.4M | 0.0× | — (loss-making) | −46.00% (below 0%: shrinking) | n/m | −195.04% (below 0%: shrinking) | 43.33% | (3,194.81%) | Compare |
| ALLR Allarity Therapeutics, Inc. | $13.2M | — (loss-making) | — (loss-making) | — | n/m | +53.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $14.0M | — | — | −46.00% | — | −18.30% | 95.61% | (441.54%) |
Pasithea Therapeutics Corp. (KTTA) key facts
- Pasithea Therapeutics Corp. (KTTA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, KTTA traded at $0.42, a market capitalization of $13.7 million.
- Return on equity was −58.4% and debt-to-equity 0.00.
Pasithea Therapeutics Corp. (KTTA) Latest News
No news at this impact. Lower the threshold for more.